Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Halozyme Therapeutics stock
Learn how to easily invest in Halozyme Therapeutics stock.
Halozyme Therapeutics Inc is a biotechnology business based in the US. Halozyme Therapeutics shares (HALO) are listed on the NASDAQ and all prices are listed in US Dollars. Halozyme Therapeutics employs 145 staff and has a trailing 12-month revenue of around $487.5 million.
How to buy shares in Halozyme Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – HALO – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Halozyme Therapeutics stock price (NASDAQ: HALO)Use our graph to track the performance of HALO stocks over time.
Halozyme Therapeutics shares at a glance
|Latest market close||$39.52|
|52-week range||$31.36 - $52.98|
|50-day moving average||$43.96|
|200-day moving average||$40.80|
|Wall St. target price||$49.57|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$2.52|
Buy Halozyme Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Halozyme Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Halozyme Therapeutics price performance over time
|1 week (2022-09-23)||1.80%|
|1 month (2022-09-01)||-2.61%|
|3 months (2022-07-01)||-11.15%|
|6 months (2022-03-28)||N/A|
|1 year (2021-10-01)||-3.02%|
|2 years (2020-10-01)||48.85%|
|3 years (2019-10-01)||155.63%|
|5 years (2017-09-29)||127.52%|
Is Halozyme Therapeutics stock undervalued or overvalued?
Valuing Halozyme Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Halozyme Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Halozyme Therapeutics's P/E ratio
Halozyme Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 15x. In other words, Halozyme Therapeutics shares trade at around 15x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Halozyme Therapeutics's EBITDA
Halozyme Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $254.9 million.
The EBITDA is a measure of a Halozyme Therapeutics's overall financial performance and is widely used to measure a its profitability.
Halozyme Therapeutics financials
|Revenue TTM||$487.5 million|
|Operating margin TTM||49.61%|
|Gross profit TTM||$326.2 million|
|Return on assets TTM||10.77%|
|Return on equity TTM||177.35%|
|Market capitalisation||$5.4 billion|
TTM: trailing 12 months
Halozyme Therapeutics share dividends
We're not expecting Halozyme Therapeutics to pay a dividend over the next 12 months.
Have Halozyme Therapeutics's shares ever split?
Halozyme Therapeutics's shares were split on a 171:40 basis on 9 December 2003. So if you had owned 40 shares the day before before the split, the next day you'd have owned 171 shares. This wouldn't directly have changed the overall worth of your Halozyme Therapeutics shares – just the quantity. However, indirectly, the new 76.6% lower share price could have impacted the market appetite for Halozyme Therapeutics shares which in turn could have impacted Halozyme Therapeutics's share price.
Halozyme Therapeutics share price volatility
Over the last 12 months, Halozyme Therapeutics's shares have ranged in value from as little as $31.36 up to $52.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Halozyme Therapeutics's is 1.2445. This would suggest that Halozyme Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Halozyme Therapeutics overview
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F.
Halozyme Therapeutics in the news
Is Halozyme Therapeutics (HALO) A Good Long-Term Investment?
We Ran A Stock Scan For Earnings Growth And Halozyme Therapeutics (NASDAQ:HALO) Passed With Ease
Argenx Seeks FDA Nod For Its Flagship Neuromuscular Treatment Formulated For Subcutaneous Injection
Frequently asked questionsWhat percentage of Halozyme Therapeutics is owned by insiders or institutions?
Currently 1.068% of Halozyme Therapeutics shares are held by insiders and 96.474% by institutions. How many people work for Halozyme Therapeutics?
Latest data suggests 145 work at Halozyme Therapeutics. When does the fiscal year end for Halozyme Therapeutics?
Halozyme Therapeutics's fiscal year ends in December. Where is Halozyme Therapeutics based?
Halozyme Therapeutics's address is: 11388 Sorrento Valley Road, San Diego, CA, United States, 92121 What is Halozyme Therapeutics's ISIN number?
Halozyme Therapeutics's international securities identification number is: US40637H1095 What is Halozyme Therapeutics's CUSIP number?
Halozyme Therapeutics's Committee on Uniform Securities Identification Procedures number is: 40637H109
More guides on Finder
How to buy YanGuFang International Group (YGF) stock when it goes public
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
Ask an Expert